ABSTRACT
OBJECTIVE: Osteoarthritis (OA) is a major source of knee pain. Mechanisms of OA knee pain are incompletely understood but include synovial pathology. We aimed to identify molecular expression patterns in the synovium associated with symptomatic knee OA. DESIGN: Snap frozen synovia were from people undergoing total knee replacement (TKR) for advanced OA, or from post-mortem (PM) cases who had not sought help for knee pain. Associations with OA symptoms were determined using discovery and validation samples, each comprising TKR and post mortem (PM) cases matched for chondropathy (Symptomatic or Asymptomatic Chondropathy). Associations with OA were determined by comparing age matched TKR and PM control cases. Real-time quantitative PCR for 96 genes involved in inflammation and nerve sensitisation used TaqMan® Array Cards in discovery and validation samples, and protein expression for replicated genes was quantified using Luminex bead assay. RESULTS: Eight genes were differentially expressed between asymptomatic and symptomatic chondropathy cases and replicated between discovery and validation samples (P<0.05 or >3-fold change). Of these, matrix metalloprotease (MMP)-1 was also increased whereas interleukin-1 receptor 1 (IL1R1) and vascular endothelial growth factor (VEGF) were decreased at the protein level in the synovium of symptomatic compared to asymptomatic chondropathy cases. MMP1 protein expression was also increased in OA compared to PM controls. CONCLUSION: Associations of symptomatic OA may suggest roles of MMP1 expression and IL1R1 and VEGF pathways in OA pain. Better understanding of which inflammation-associated molecules mediate OA pain should inform refinement of existing therapies and development of new treatments.
Subject(s)
Gene Expression Regulation , Matrix Metalloproteinase 1/genetics , Osteoarthritis, Knee/genetics , Receptors, Interleukin-1 Type I/genetics , Synovial Membrane/metabolism , Vascular Endothelial Growth Factor A/genetics , Aged , Biomarkers/metabolism , Cross-Sectional Studies , Disease Progression , Female , Gene Expression Profiling/methods , Humans , Male , Matrix Metalloproteinase 1/biosynthesis , Middle Aged , Osteoarthritis, Knee/diagnosis , Osteoarthritis, Knee/metabolism , RNA/genetics , Receptors, Interleukin-1 Type I/biosynthesis , Retrospective Studies , Severity of Illness Index , Synovial Membrane/pathology , Vascular Endothelial Growth Factor A/biosynthesisABSTRACT
BACKGROUND: Hyperalimentation for 4 weeks is associated with raised liver enzymes and liver fat content (LFC), which are two common features found in individuals with diabetes. AIM: We evaluated the effect of two mixed meal challenges on LFC, liver enzymes and serum bio-markers of liver injury and fibrosis in 16 healthy volunteers (HV) and subjects with type 2 diabetes (T2DM). METHODS: Subjects (HV: 9 male, 7 female, aged 57.9 ± 1.7 years, body mass index (BMI) 27.1 kg/m(2); and T2DM: 11 male, 5 female, aged 62.1 ± 1.3 years, BMI 28.0 ± 0.4 kg/m(2)) consumed two meals at 1 h (884 kcal) and at 6 h (1,096 kcal). LFC determined by (1)H magnetic resonance spectroscopy, serum levels of liver enzymes, hyaluronic acid (HA), procollagen III N-terminal peptide (P3NP) and tissue inhibitor metalloproteinase-1 (TIMP-1) were estimated at time 0 (fasting) and 9 h (postprandial). RESULTS: Fasting LFC was higher in the T2DM group 7.6 % (4.9, 15.4) [median (inter-quartile range)] than in the HV group 2.3 % (0.8, 5.1) (p < 0.05) while levels of HA, P3NP and TIMP-1 were similar. Following the meal challenge there was no significant change in LFC. Subjects with T2DM had higher post-prandial rise in alanine transaminase (ALT) (p = 0.014), serum HA (p = 0.007) and P3NP (p = 0.015) compared with HV. Fasting LFC correlated with a greater post-prandial increase in P3NP levels in all subjects (Pearson correlation r = 0.53, p = 0.001). CONCLUSIONS: In subjects with T2DM, a mixed meal challenge is associated with a significant elevation in the serum levels of ALT, HA and P3NP without significant changes in LFC. These markers should be performed in the fasted state.
Subject(s)
Alanine Transaminase/blood , Biomarkers/blood , Diabetes Mellitus, Type 2/blood , Eating , Liver Cirrhosis/blood , Blood Glucose/analysis , Diabetes Mellitus, Type 2/enzymology , Female , Humans , Hyaluronic Acid/blood , Insulin/blood , Liver Cirrhosis/enzymology , Magnetic Resonance Spectroscopy , Male , Middle Aged , Peptide Fragments/blood , Procollagen/blood , Statistics, Nonparametric , Tissue Inhibitor of Metalloproteinase-1/bloodABSTRACT
BACKGROUND: The chemokine CXCL12 and its cognate receptor, CXCR4, have been implicated in numerous tumour types where expression promotes tumour growth, angiogenesis, metastasis and suppresses tumour immunity. METHODS: Using a tissue microarray of 289 primary ovarian cancers coupled to a comprehensive database of clinicopathological variables, the expression of CXCL12 and CXCR4 was assessed by immunohistochemistry and its impact in terms of survival and clinicopathological variables was determined. RESULTS: Patients whose tumours expressed high levels of CXCL12 had significantly poorer survival (P=0.026) than patients whose tumours failed to produce this chemokine. Lack of CXCL12 expression within tumours was associated with a 51-month survival advantage for patients when compared with patients whose tumours expressed high levels of CXCL12. FIGO stage, adjuvant chemotherapy and the absence of macroscopic disease after surgery were all shown to predict prognosis independently of each other in this cohort of patients. CXCL12 was independently predictive of prognosis on multivariate analysis (P=0.016). There was no correlation between CXCL12 and any clinicopathological variable. CONCLUSION: The chemokine CXCL12 is an independent predictor of poor survival in ovarian cancer. High expression of CXCL12 was seen in only 20% of the tumours, suggesting a role for anti-CXCL12/CXCR4 therapy in the management of these patients.
Subject(s)
Chemokine CXCL12/metabolism , Ovarian Neoplasms/metabolism , Adult , Biomarkers, Tumor/analysis , Disease-Free Survival , Female , Humans , Middle Aged , Ovarian Neoplasms/mortality , Ovarian Neoplasms/pathology , Prognosis , Receptors, CXCR4/metabolism , Survival AnalysisABSTRACT
Research into aberrant glycosylation and over-expression of glycolipids on the surface of the majority of cancers, coupled with a knowledge of glycolipids as functional molecules involved in a number of cellular physiological pathways, has provided a novel area of targets for cancer immunotherapy. This has resulted in the development of a number of vaccines and monoclonal antibodies that are showing promising results in recent clinical trials.
Subject(s)
Antigens, Neoplasm/immunology , Cancer Vaccines/therapeutic use , Glycolipids/antagonists & inhibitors , Immunotherapy/methods , Molecular Targeted Therapy/methods , Neoplasms/therapy , Animals , Antibodies, Monoclonal/immunology , Antibodies, Monoclonal/therapeutic use , Cancer Vaccines/immunology , Ceramides/metabolism , Clinical Trials as Topic , G(M3) Ganglioside/analogs & derivatives , G(M3) Ganglioside/immunology , Gangliosides/immunology , Glycolipids/immunology , Glycolipids/metabolism , Glycosylation , Humans , Lewis Blood Group Antigens/immunology , Neoplasms/metabolism , Trisaccharides/immunologyABSTRACT
Single shot vaccines of tetanus toxoid (TT) were manufactured using the NanoMix process - a low temperature solvent free encapsulation technology using supercritical fluids. The formulations were injected into mice, and compared to multiple injections of a commercially available alum adsorbed TT vaccine. After 5 months the antibody titres were found to be similar for both the alum adsorbed and microparticle formulations, demonstrating for the first time the potential of formulating antigens in PLA microparticles using the supercritical fluid (NanoMix) technique to produce single shot vaccines. The results are likely to be due to the maintenance of toxoid bioactivity and some degree of sustained release of the encapsulated antigens, resulting in repeated stimulation of antigen presenting cells eliminating the need for multiple immunisations. This demonstrates the potential of this supercritical fluid processing technique to reduce the need for booster doses in a vaccine regimen.
Subject(s)
Drug Compounding/methods , Drug Delivery Systems , Tetanus Toxoid/administration & dosage , Tetanus Toxoid/chemistry , Adjuvants, Immunologic/administration & dosage , Alum Compounds , Animals , Control Groups , Delayed-Action Preparations , Dose-Response Relationship, Drug , Drug Administration Schedule , Drug Carriers , Female , Immunization , Lactic Acid/chemistry , Mice , Mice, Inbred BALB C , Particle Size , Placebos , Polyesters , Polymers/chemistry , Tetanus/immunology , Tetanus Toxoid/immunology , Vaccines/administration & dosage , Vaccines/chemistry , Vaccines/immunologyABSTRACT
Antigen/antibody complexes can efficiently target antigen presenting cells to allow stimulation of the cellular immune response. Due to the difficulty of manufacture and their inherent instability complexes have proved inefficient cancer vaccines. However, anti-idiotypic antibodies mimicking antigens have been shown to stimulate both antibody and T cell responses. The latter are due to T cell mimotopes expressed within the complementarity-determining regions (CDRs) of antibodies that are efficiently presented to dendritic cells in vivo. Based on this observation we have designed a DNA vaccine platform called ImmunoBody, where cytotoxic T lymphocyte (CTL) and helper T cell epitopes replace CDR regions within the framework of a human IgG1 antibody. The ImmunoBody expression system has a number of design features which allow for rapid production of a wide range of vaccines. The CDR regions of the heavy and light chain have been engineered to contain unique restriction endonuclease sites, which can be easily opened, and oligonucleotides encoding the T cell epitopes inserted. The variable and constant regions of the ImmunoBody are also flanked by restriction sites, which permit easy exchange of other IgG subtypes. Here we show a range of T cell epitopes can be inserted into the ImmunoBody vector and upon immunization these T cell epitopes are efficiently processed and presented to stimulate high frequency helper and CTL responses capable of anti-tumor activity.
Subject(s)
Antibodies, Anti-Idiotypic/immunology , Cancer Vaccines/immunology , Epitopes, T-Lymphocyte/immunology , Melanoma, Experimental/therapy , Vaccines, DNA/immunology , Amino Acid Sequence , Amino Acid Substitution , Animals , Antibodies, Anti-Idiotypic/genetics , Antibodies, Anti-Idiotypic/therapeutic use , Cancer Vaccines/genetics , Cancer Vaccines/therapeutic use , Complementarity Determining Regions/genetics , Complementarity Determining Regions/immunology , Epitopes, T-Lymphocyte/genetics , Genetic Vectors/immunology , Humans , Immunization Schedule , Immunoglobulin G/immunology , Injections, Intradermal , Lymphocyte Activation , Melanoma, Experimental/prevention & control , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Mice, Transgenic , Molecular Sequence Data , T-Lymphocytes, Cytotoxic/immunology , T-Lymphocytes, Helper-Inducer/immunology , Vaccines, DNA/genetics , Vaccines, DNA/therapeutic useABSTRACT
We assessed T-cell responses in young osteosarcoma patients vaccinated with 105AD7, 1-6 months after having received chemotherapy. 105AD7 is a human anti-idiotypic antibody mimicking CD55, a glycoprotein that protects from attack by complement and which is overexpressed on osteosarcoma cells. Seven out of 21 investigated patients made a IFN-gamma T-cell response against the vaccine, 105AD7 as assessed by ELISPOT. Cytokine secretion was analysed using Luminex assays and revealed TNF-alpha and GM-CSF responses not only to the vaccine but also towards the native antigen, CD55, in 5 / 14 (36%) of investigated patients. Importantly, the Luminex assay was found to be more sensitive than the more established T-cell assays (ELISPOT and proliferation assay), since responses towards the native antigen were recorded in this assay. Clinical responses and induction of immune responses to both the anti-idiotype and the native CD55 antigen support the use of CD55 as a target in cancer treatment.
Subject(s)
Antibodies, Anti-Idiotypic/immunology , Bone Neoplasms/immunology , Cancer Vaccines/immunology , Immunization, Passive , Osteosarcoma/immunology , T-Lymphocytes/immunology , Antibodies, Anti-Idiotypic/administration & dosage , Antibodies, Monoclonal/administration & dosage , Antibodies, Monoclonal/immunology , CD55 Antigens/immunology , Cancer Vaccines/administration & dosage , Cell Proliferation , Granulocyte-Macrophage Colony-Stimulating Factor/biosynthesis , Granulocyte-Macrophage Colony-Stimulating Factor/immunology , Humans , Immunoenzyme Techniques , Injections, Intramuscular , Injections, Subcutaneous , Interferon-gamma/biosynthesis , Interferon-gamma/immunology , T-Cell Antigen Receptor Specificity , T-Lymphocytes/metabolism , Treatment Outcome , Tumor Necrosis Factor-alpha/biosynthesis , Tumor Necrosis Factor-alpha/immunology , United KingdomABSTRACT
105AD7 is a human monoclonal antibody that mimics the complement regulatory protein, CD55, overexpressed by many solid tumours including osteosarcoma. This study was designed to assess the toxicity and efficacy of this vaccine in a young age group of patients within 1-6 months of myleosuppressive chemotherapy. Out of 28, 20 (71%, 95% CI 51-87%) patients showed a significant T-cell proliferation response in vitro to the 105AD7 protein but not to human IgG. Furthermore, 13 out of 22 (59%, 95% CI 36-79%) patients showed antigen-specific gammaIFN secretion (range 20-370 U/ml). Nine out of 28 (32%, 95% CI 16-52%) patients made weak antibody responses to CD55. This study showed that 105AD7 was well tolerated in younger patients with osteosarcoma. In addition, two patients with possible clinical responses were given compassionate permission to continue immunisation quarterly for 2 years. They both remain alive and disease free 5.8 and 6.5 years from original diagnosis of osteosarcoma and showed no adverse effects of repeated immunisation. In conclusion, the majority of patients showed measurable T helper responses when vaccination was commenced within a 6-month window of intensive chemotherapy with no clinically significant toxicity. Future clinical trials incorporating immune stimulation strategies should include early introduction of vaccines during the highest risk period for relapse.
Subject(s)
Antibodies, Anti-Idiotypic/immunology , Antibodies, Anti-Idiotypic/therapeutic use , Cancer Vaccines/therapeutic use , Osteosarcoma/therapy , Adult , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , CD55 Antigens/immunology , Cell Proliferation/drug effects , Enzyme-Linked Immunosorbent Assay , Female , Humans , Interferon-gamma/drug effects , Interferon-gamma/immunology , Osteosarcoma/immunology , T-Lymphocytes/drug effects , T-Lymphocytes/immunologyABSTRACT
Carcinoembryonic antigen (CEA) is a cell surface protein over-expressed by a wide range of tumours. The mouse anti-idiotypic antibody, 708, mimics CEA and can induce both antibody and T cell responses that specifically recognise this antigen. Sequence analysis of 708 revealed homology with a previously identified HLA-A3 T cell epitope in CEA but not to other closely related molecules. 708 was chimerised to a human IgG1 to allow Fc targeting of APCs and was deimmunised to remove unwanted T cell epitopes. The chimerised and deimmunised, but not the mouse 708, could stimulate CTL, proliferation and gammaIFN responses in vitro in normal (HLA-A3, DR1) individuals. Furthermore, the CTLs killed tumour cells expressing CEA suggesting that this deimmunised antibody could be a useful vaccine for solid tumours.
Subject(s)
Cancer Vaccines/immunology , Carcinoembryonic Antigen/immunology , Immunity, Cellular/physiology , Interferon-gamma/biosynthesis , T-Lymphocytes, Cytotoxic/immunology , T-Lymphocytes/immunology , Algorithms , Amino Acid Sequence , Amino Acid Substitution , Animals , Cancer Vaccines/genetics , Carcinoembryonic Antigen/genetics , Cell Line , Cloning, Molecular , Cytokines/biosynthesis , Cytotoxicity Tests, Immunologic , Epitopes/immunology , HLA Antigens/immunology , Humans , Lymphocyte Activation/drug effects , Lymphocyte Count , Mice , Molecular Mimicry , Molecular Sequence Data , Recombinant Fusion Proteins/immunologyABSTRACT
The last 10 years have seen a growth in the number of tumour antigens identified from immune responses raised in patients. The discovery that tumours can be recognised by the immune system stimulated a great deal of work characterising the molecular mechanisms underlying immune recognition. This in turn has led to an impressive array of immunological approaches to the generation of cancer vaccines; these range from molecularly defined T cell epitopes, antibody-based vaccines, cytokine therapies, immune modulators and DNA vaccines, to whole cell vaccines and, more recently, combinations of these methods. Many of these approaches have entered Phase I/II trials and have shown interesting clinical results. Moreover, they have extended our knowledge of the immune system and our understanding of the mechanisms required to design a successful cancer vaccine. This review outlines some of the approaches that have led to some of these vaccines entering Phase III clinical trials, discusses their modes of action and reports on their current status in trial.
Subject(s)
Cancer Vaccines/therapeutic use , Neoplasms/therapy , Adjuvants, Immunologic/therapeutic use , Cancer Vaccines/immunology , Clinical Trials, Phase III as Topic , Cytokines/immunology , Dendritic Cells/immunology , Humans , Neoplasms/immunologyABSTRACT
This study prospectively correlated the level of expression of CD55 on tumours with 7-year survival in 136 colorectal cancer patients. Patients with tumours expressing high levels of CD55 had a significantly worse survival (24%) than patients with low CD55 levels (50%, p<0.02). A similar difference was seen for patients (Duke's B or C) with a high risk of recurrence (29% vs 58%, p<0.05). Furthermore, there was a progressive deterioration in prognosis with increasing antigen expression ( p=0.01). It remains unclear if CD55 is overexpressed by tumours to protect them from complement or if it is related to the recent observation that CD55 is a ligand for the T-cell activation antigen CD97. However, it is a marker of aggression, as colorectal cancer patients whose tumours overexpress CD55 have a significantly reduced 7-year survival.
Subject(s)
CD55 Antigens/metabolism , Colorectal Neoplasms/metabolism , Aged , Aged, 80 and over , Antigens, Neoplasm/metabolism , Biomarkers, Tumor/metabolism , Colorectal Neoplasms/pathology , Complement System Proteins , Female , Fluorescent Antibody Technique , Humans , Male , Middle Aged , Neoplasm Staging , Prognosis , Prospective Studies , Survival RateABSTRACT
CD55 is a complement regulatory protein expressed by cells to protect them from bystander killing by complement. CD55 is over-expressed 2-100-fold on tumour cells and is deposited in large amounts within tumour matrix. Vascular endothelial growth factor (VEGF) produced by tumours to stimulate angiogenesis, also up-regulates endothelial cell surface expression of CD55 and stimulates the release of matrix degrading metalloproteinases. This study investigated the effects of VEGF on CD55 deposition into matrix and the release of CD55 by metalloproteinases. In contrast to inflammatory cytokines, CD55 was up-regulated by VEGF at the cell surface and within the extracellular matrix (ECM). Interestingly, human umbilical vein endothelial cells (HUVEC) exposed to VEGF released similar amounts of CD55 into the ECM as a tumour cell line expressing 50-fold higher level of CD55 on its cell surface. Furthermore, in contrast to earlier studies, both tumour and HUVEC-derived CD55 was functionally active. However, in contrast to papain that degrades CD55, and collagenase that fails to release CD55, MMP-7 released intact CD55 from ECM. This suggests that it may have a further role to play in protecting cells during inflammation and invasion.
Subject(s)
CD55 Antigens/immunology , Colorectal Neoplasms , Complement C3b/immunology , Osteosarcoma , CD55 Antigens/metabolism , Complement C3b/metabolism , Endothelial Growth Factors/pharmacology , Endothelium, Vascular/cytology , Endothelium, Vascular/drug effects , Extracellular Matrix/immunology , Extracellular Matrix/metabolism , Humans , Intercellular Signaling Peptides and Proteins/pharmacology , Lymphokines/pharmacology , Matrix Metalloproteinase 7/metabolism , Tumor Cells, Cultured/immunology , Tumor Cells, Cultured/metabolism , Umbilical Veins/cytology , Vascular Endothelial Growth Factor A , Vascular Endothelial Growth FactorsABSTRACT
Anti-idiotypic antibodies that mimic tumour-associated antigens can stimulate anti-tumour T-cell responses. In this article, we have studied the role of Fc in the presentation of T-cell epitopes by 2 anti-idiotypic antibodies, 105AD7 and 708. The human monoclonal antibody 105AD7, which mimics CD55, stimulated strong in vitro T-cell proliferation, gammaIFN secretion and redirected cytotoxicity in unprimed T cells from healthy donors. However, removal of the Fc region of the anti-idiotype reduced the sensitivity of the assay 1,000-fold, as did inhibiting Fc uptake of the anti-idiotype by an excess of human IgG. The mouse anti-idiotype 708, which mimics CEA, failed to stimulate in vitro T-cell responses on unprimed T cells from healthy donors. However, when a human IgG1 Fc region replaced its mouse Fc region, the anti-idiotype induced T-cell proliferation, gammaIFN secretion and redirected cytotoxicity in lymphocytes from unimmunised donors. Human anti-idiotypes are therefore good immunogens since they target Fc receptors on antigen-presenting cells, allowing efficient stimulation of both helper and cytotoxic T-cell responses. The immunogenicity of other anti-idiotypes may therefore be enhanced by human Fc targeting of antigen-presenting cells.
Subject(s)
Antibodies, Anti-Idiotypic/immunology , Antigen-Presenting Cells/immunology , Receptors, Fc/immunology , T-Lymphocytes, Cytotoxic/immunology , T-Lymphocytes, Helper-Inducer/immunology , Animals , Antigen-Presenting Cells/metabolism , Humans , Immunophenotyping , Lymphocyte Activation , Mice , Vaccines/immunologyABSTRACT
CD55 is a protein that protects cells from complement-mediated attack. 791Tgp72 is an antigen which has been used successfully as a target for both tumour imaging and cancer vaccines. 791Tgp72 has recently been identified as CD55. Quantitative expression of CD55 in the tumour environment was therefore studied. Tumour cells showed a 4-100-fold increase in CD55 cell surface expression when compared to normal cells. Immunohistochemical staining of colorectal tumours also revealed high expression of CD55 in the stroma. To examine the source of this stromal CD55 the ability of both epithelial cells and endothelial cells to produce extracellular CD55 was measured. Tumour cell lines deposit CD55 into their extracellular matrix (ECM) in direct proportion to their cell surface expression. In contrast the ECM from HUVEC cells contained large amounts of CD55 despite expressing low levels of CD55 on their cell surface. Furthermore expression of CD55 on HUVEC cells was increased by exposure to VEGF. Although it remains unclear why CD55 is upregulated in the tumour environment its high level of expression on tumour cells and associated endothelium may explain why it is a good target for both imaging and immunotherapy.
Subject(s)
Antigens, Neoplasm/analysis , CD55 Antigens/analysis , Colorectal Neoplasms/immunology , Stomach Neoplasms/immunology , Blotting, Western , Fluorescent Antibody Technique, Indirect , Humans , Immunohistochemistry , Tumor Cells, CulturedABSTRACT
Complement is an enzymatic cascade that results in the release of pro-inflammatory anaphylatoxins, C3b deposition and the assembly of the membrane attack complex (MAC), which results in cell lysis. Cells express complement regulatory proteins or inhibitors to protect themselves from bystander attack by complement. Expression of the complement-regulatory proteins CD55, CD46 and CD59 are deregulated in cancer with tumors showing loss of one or more inhibitors and strong overexpression of others. This results in tumors that are resistant to attack by complement and is a major limitation in the use of monoclonal antibodies as monotherapies. However, tumor sensitivity to complement can be restored by co-administration of antibodies that bind to the functional domains of complement-regulatory proteins. Overexpression of complement-regulatory proteins on tumors also makes them potential targets for cancer vaccines. However, these vaccines have to be carefully designed to induce immune responses that recognize inhibitors overexpressed on tumors and that do not detect the levels expressed by normal cells. A human anti-idiotypic antibody that mimics CD55 has been used successfully in over 200 colorectal cancer and osteosarcoma patients. 70% Of patients show CD55-specific immune responses with no associated toxicity. Similar vaccines targeting CD46 and CD59 would eliminate any cell overexpressing a complement inhibitor. Any remaining tumor cell or any tumor cell that loses complement-regulatory proteins in response to therapy would become highly susceptible to in situ complement deposition. In summary, targeting complement-regulatory proteins is a very attractive approach to tumor therapy, although great care must be taken in preventing normal tissue recognition as this could lead to uncontrolled complement deposition and massive cell lysis.
Subject(s)
Antibodies, Monoclonal/therapeutic use , Cancer Vaccines/therapeutic use , Complement System Proteins/metabolism , Neoplasms/therapy , Vaccination/methods , Animals , Antibodies, Anti-Idiotypic/chemistry , Antibodies, Anti-Idiotypic/pharmacology , Antibodies, Anti-Idiotypic/therapeutic use , Antibodies, Monoclonal/immunology , Antibodies, Monoclonal/metabolism , Antigens, CD/chemistry , Antigens, CD/metabolism , Binding Sites , CD55 Antigens/chemistry , CD55 Antigens/metabolism , CD59 Antigens/chemistry , CD59 Antigens/metabolism , Cancer Vaccines/immunology , Cancer Vaccines/metabolism , Clinical Trials as Topic , Complement C3-C5 Convertases/antagonists & inhibitors , Complement Inactivator Proteins/chemistry , Complement Inactivator Proteins/metabolism , Complement Membrane Attack Complex/antagonists & inhibitors , Complement System Proteins/physiology , Humans , Membrane Cofactor Protein , Membrane Glycoproteins/chemistry , Membrane Glycoproteins/metabolism , Neoplasms/immunology , Neoplasms/metabolismABSTRACT
BACKGROUND: A mouse monoclonal antibody (2C7/IgG2b kappa) has been described recently, which is directed against the major house dust mite allergen Der p 1, and whose epitope specificity is representative of a major component of the human IgE anti-Der p 1 response. AIMS: To characterise an anti-idiotypic antibody (2G10/IgG1 kappa) raised against monoclonal antibody 2C7 as surrogate human IgE anti-Der p 1. METHODS: The specificity of the anti-idiotype antibody 2G10 was determined by competitive inhibition experiments using human and mouse immunoglobulins of known VH gene families. The epitope recognised by monoclonal antibody 2G10 was located on the molecular model of the Fv (fragment variable) region of monoclonal antibody 2C7. RESULTS: The data suggest that monoclonal antibody 2G10 is directed against a crossreactive idiotype on human IgE that is shared by polyclonal IgG. Competitive inhibition studies against human immunoglobulins, representative of VH2, VH3, and VH4 gene families, showed that monoclonal antibody 2G10 is mostly likely to be directed against sequences encoded by either VH3 or VH4 genes. The fact that monoclonal antibody 2G10 binds to the humanized (complementarity determining region (CDR) grafted) CAMPATH-1H antibody, but not to the original rat CAMPATH-1 YTH34.5.6 antibody, indicates that it is directed against a framework region rather than the CDRs. Analysis of amino acids in the VH region for charge, hydrophobicity, and accessibility suggests that reactivity with monoclonal antibody 2G10 is defined by a hexapeptide spanning residues 74-79 within framework region 3. CONCLUSION: The anti-idiotype monoclonal antibody 2G10 could potentially be used as a probe for determining the contribution of the VH3 and VH4 gene segments to antigenic specificity.
Subject(s)
Antibodies, Anti-Idiotypic/immunology , Antibodies, Monoclonal/immunology , Glycoproteins/immunology , Immunoglobulin E/immunology , Amino Acid Sequence , Animals , Antibodies, Anti-Idiotypic/genetics , Antibodies, Monoclonal/genetics , Antibody Specificity , Antigens, Dermatophagoides , Cross Reactions , Dust , Epitopes , Genes, Immunoglobulin , Humans , Immunoglobulin G/immunology , Mice , Mites/immunology , Molecular Sequence Data , Sequence AlignmentABSTRACT
105AD7 is a human anti-idiotypic antibody that recognises the binding site of the anti-tumour antibody 791T/36 and can thereby mimic the CD55 antigen. The molecular basis of 105AD7 mimicry has been identified with 3 CDR regions of 105AD7 showing similarity to 3 regions of CD55. These regions have been analysed for potential T-cell epitopes, and sequences that are predicted to bind to HLA/A1, 3,24 and to HLA/DR1,3,7 have been identified within the CDRH3 region of 105AD7. These epitopes should be stimulating CD8 and CD4 responses, respectively. This prediction was tested on 12 colorectal cancer patients receiving 105AD7 therapy. There was good concordance in 10 of 11 patients between accumulation of CD8RO cells or tumour killing and expression of HLA/A1,3,24. The only patient who failed to respond had a non-permissive class II haplotype and failed to show a helper response. Again 10 of 11 patients showing accumulation of CD4RO cells, in vitro blastogenesis responses, enhanced IL-2 or enhanced NK activity expressed one or more of the HLA/DR1,3,7 haplotypes. Although there was a consistent accumulation of CD45RO cells following 14 of 18 immunisations, only one patient showed a sustained memory response. Our results suggest that 105AD7 can stimulate CD4 and CD8 responses in patients with the appropriate haplotype. However, it may be necessary to continue to immunise, since few patients produce a sustained memory response.
Subject(s)
Antibodies, Anti-Idiotypic/immunology , Cancer Vaccines/administration & dosage , Cancer Vaccines/immunology , Colorectal Neoplasms/immunology , T-Lymphocytes, Cytotoxic/immunology , T-Lymphocytes, Helper-Inducer/immunology , Antibodies, Anti-Idiotypic/administration & dosage , CD4-Positive T-Lymphocytes/immunology , CD55 Antigens/immunology , CD8-Positive T-Lymphocytes/immunology , Colorectal Neoplasms/therapy , Dose-Response Relationship, Immunologic , Epitopes, T-Lymphocyte/immunology , HLA-DR Antigens/immunology , Histocompatibility Testing , Humans , Immunization, Secondary , Immunologic Memory/drug effects , Immunophenotyping , Leukocyte Common Antigens/biosynthesisABSTRACT
The 791Tgp72 antigen has been used successfully as a target for tumor imaging and T-cell immunotherapy. We have characterized this antigen using the monoclonal antibody 791T/36 as a 72/66 kDa doublet. NH2-terminal protein sequencing of the two bands revealed identity with the complement regulatory protein CD55. Antibodies recognizing different domains of CD55 were also shown to bind to the purified 791Tgp72, although sequence analysis of the cDNA cloned from 791T tumor cells showed 100% homology with CD55 and transfection of the cDNA into antigen-negative CHO cells resulted in binding of 791T/36. This identifies the tumor antigen 791Tgp72 as CD55. This protein protects cells from complement attack; however, it can also transduce signals in lymphocytes and is a ligand for CD97, expressed by activated T cells. These results suggest that CD55 plays a role in signaling between the innate and adaptive immune responses. It is therefore a very intriguing target, because absence of the molecule makes the tumor cells susceptible to complement, whereas protective overexpression results in the antigen being a target for T-cell immunotherapy.
Subject(s)
Bone Neoplasms/pathology , CD55 Antigens/immunology , Cancer Vaccines , Neoplasm Proteins/immunology , Osteosarcoma/pathology , Amino Acid Sequence , Animals , Antibodies, Anti-Idiotypic/immunology , Antibodies, Monoclonal/immunology , Bone Neoplasms/immunology , CHO Cells , Complement System Proteins/physiology , Cricetinae , Cricetulus , DNA, Complementary/genetics , DNA, Neoplasm/genetics , Gene Expression Regulation, Neoplastic , Lymphocyte Activation , Membrane Glycoproteins/metabolism , Molecular Sequence Data , Osteosarcoma/immunology , Sequence Analysis , T-Lymphocytes/metabolism , Transfection , Tumor Cells, CulturedABSTRACT
Clinical studies with the human anti-idiotypic antibody 105AD7 have clearly shown that 791Tgp72 is a good target antigen for cell-mediated immunity. No antibody-related toxicity was observed in any of the 135 patients entered into phase I/II clinical trials of 105AD7, whereas both helper and cytotoxic T-cell responses were induced. The helper responses were exemplified by induction of interleukin-2 (IL-2), antigen-specific blastogenesis, and enhanced natural killer (NK) activity. Anti-tumor cytotoxicity was measured directly and was supported by activation of circulating CD8 cells. In this study, it is shown that a 100-microgram injection of 105AD7 was more effective than the 200-microgram dose. Enhanced IL-2 production was observed following 15/19 injections of 100 micrograms of 105AD7 whereas only 4/11 injections of 200 micrograms of 105AD7 induced responses (p < 0.02). Similarly, time to progression was significantly (p < 0.05) slower (median 6 m) in patients injected with 100 micrograms than patients receiving the higher dose, suggesting that 100 micrograms or lower may be the optimal dose. The standard dose for hepatitis vaccination is 10 micrograms. In vitro blastogenesis assays on naive donors have shown that a dose of 105AD7, which is either too high or too low, fails to activate T cells. The optimal dose in vitro is 10 ng.